Bachem stock gains on SIX as investors look ahead to next results

Published on 09/21/2026 at 19:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock traded higher on SIX on September 21, 2026, with the shares up around 1.3 percent intraday. Recent half-year figures and analyst expectations for 2026 earnings give investors a clearer view of the Swiss peptide maker’s momentum.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding AG stock (ISIN CH0012530207) traded firmer on the SIX Swiss Exchange on September 21, 2026, with the shares around 1.3 percent higher intraday near 79.60 CHF as investors positioned ahead of upcoming updates on the company’s pipeline and capacity expansion.

Intraday move and recent trading levels

According to finanzen.ch, Bachem shares were quoted at 79.60 CHF on SIX at 12:28 p.m. local time on September 21, 2026, up 1.3 percent from the opening level of 78.55 CHF, with a session high reported at 80.10 CHF and trading volume of 10,328 shares in the SPI index.

The same overview from finanzen.ch noted an earlier quote of 78.90 CHF at 9:28 a.m. on September 21, 2026, up 0.4 percent at that point, underlining that the stock spent the morning moderately higher within the SPI as it moved from the 78.55 CHF opening level toward the intraday high region.

Fundamental backdrop and earnings expectations

For fundamental context, analysts cited by finanzen.ch currently estimate Bachem’s earnings per share for fiscal year 2026 at 2.40 CHF, providing a benchmark for investors assessing valuation against the current share price.

Bachem’s most recent published results before September 21, 2026, stem from its latest interim reporting period, which the company summarizes on its investor relations pages at Bachem, including revenue development, profitability metrics and guidance for capacity and portfolio expansion; these figures cover the most recent half-year and fiscal-year periods and form the base for the 2026 EPS estimates cited by external portals.

Position within the Swiss market

As finanzen.ch reports, Bachem shares were counted among the day’s winners in the SPI index on September 21, 2026, with the SPI quoted around 19,748 points while Bachem traded close to 79.60 CHF, indicating that the stock slightly outperformed the broader Swiss market during the midday session.

For investors, the combination of a modest intraday gain, a recent intraday high at 80.10 CHF and external expectations of 2.40 CHF earnings per share for 2026 frames Bachem as a specialty pharma supplier whose valuation remains closely tied to progress in peptide production capacity and contract pipeline.

Stock level and closing perspective

With Bachem stock changing hands around 79.60 CHF on SIX as of September 21, 2026, the shares remain in a range just below the intraday high of 80.10 CHF reported that day, giving investors a reference level for the Swiss peptide producer’s current market pricing.